Abstract
Ribonucleotide Reductase (RNR) plays a critical role in DNA synthesis, and is a well-recognized target for cancer chemotherapeutic and antiviral agents. RNR inhibition precludes DNA transcription and repair, from which results cell apoptosis. Many regulation checkpoints concerning RNR activity have been unravelled through the last two decades, with potential use to inhibit enzyme activity. This was accomplished by researchers from different but complementary areas, and from which several and different inhibitors have resulted. The volume of these studies has generated over 4000 articles since the discovery of RNR in 1960. This review summarises patents and papers during the period 1958 - 2005 dealing with the present understanding of ribonucleotide reductase biochemistry, mechanism of action and the most relevant data concerning RNR inhibition. Special attention is given to the inhibitors that have been patented and are currently in clinical use.
Keywords: Ribonucleotide reductase, Inhibitors, antisense, dimerization, radical-scavengers, iron chelators, substrate analogues, allosteric, theoretical results, mechanisms
Recent Patents on Anti-Cancer Drug Discovery
Title: Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Volume: 2 Issue: 1
Author(s): S. A. Nuno M. F. S. A. Cerqueira, Pedro A. Fernandes and Maria J. Ramos
Affiliation:
Keywords: Ribonucleotide reductase, Inhibitors, antisense, dimerization, radical-scavengers, iron chelators, substrate analogues, allosteric, theoretical results, mechanisms
Abstract: Ribonucleotide Reductase (RNR) plays a critical role in DNA synthesis, and is a well-recognized target for cancer chemotherapeutic and antiviral agents. RNR inhibition precludes DNA transcription and repair, from which results cell apoptosis. Many regulation checkpoints concerning RNR activity have been unravelled through the last two decades, with potential use to inhibit enzyme activity. This was accomplished by researchers from different but complementary areas, and from which several and different inhibitors have resulted. The volume of these studies has generated over 4000 articles since the discovery of RNR in 1960. This review summarises patents and papers during the period 1958 - 2005 dealing with the present understanding of ribonucleotide reductase biochemistry, mechanism of action and the most relevant data concerning RNR inhibition. Special attention is given to the inhibitors that have been patented and are currently in clinical use.
Export Options
About this article
Cite this article as:
Nuno M. F. S. A. Cerqueira S. A. , Fernandes A. Pedro and Ramos J. Maria, Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (1) . https://dx.doi.org/10.2174/157489207779561408
DOI https://dx.doi.org/10.2174/157489207779561408 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Finding Drug Targets Through Analysis of the Platelet Transcriptome
Current Pharmaceutical Design Chronic Myelogenous Leukemia
Current Cancer Therapy Reviews The Fate of Nanoparticles In Vivo and the Strategy of Designing Stealth Nanoparticle for Drug Delivery
Current Drug Targets Compendious Review on Bioactive Constituents and Pharmacotherapeutic Profile of Heliotropium indicum Linn
The Natural Products Journal Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Ferroptosis Inducers for Prostate Cancer Therapy
Current Medicinal Chemistry Self-Assembling Peptides: Potential Role in Tumor Targeting
Current Pharmaceutical Biotechnology Ribonucleotide Reductase as One Important Target of [Tris(1,10- phenanthroline)lanthanum(III)] Trithiocyanate (KP772)
Current Cancer Drug Targets Polysulfated/Sulfonated Compounds for the Development of Drugs at the Crossroad of Viral Infection and Oncogenesis
Current Pharmaceutical Design Internal Ribosome Entry Site Elements in Eukaryotic Genomes
Current Genomics Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Quinoline-3-carboxylate Derivatives: A New Hope as an Antiproliferative Agent
Anti-Cancer Agents in Medicinal Chemistry Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review
Current Medical Imaging Stem Cell Transplantation for Chronic Myeloid Leukemia (CML): Current Indications and Perspectives
Current Cancer Drug Targets From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Ribozyme- and Deoxyribozyme-Strategies for Medical Applications
Current Drug Targets New Functions of the Inositol Polyphosphate 5-Phosphatases in Cancer
Current Pharmaceutical Design